D.E. Shaw & Co’s Bicycle Therapeutics BCYC Stock Holding History

D.E. Shaw & Co’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,548	Closed	-$153K	–	4544
2025 Q4	$153K	Buy	+21,548	New	+$159K	﹤0.01%	4366

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSK plc London $599M AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's BCYC Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 21,548 shares — an estimated $153K sold.

D.E. Shaw & Co first reported a position in BCYC in Q4 2025 and held it in 1 quarter. The position peaked at $153K in Q4 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

D.E. Shaw & Co reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
D.E. Shaw & Co sold 21,548 Bicycle Therapeutics shares in Q1 2026, an estimated $153K.
D.E. Shaw & Co first reported a position in Bicycle Therapeutics in Q4 2025 and held it in 1 quarter.
D.E. Shaw & Co's Bicycle Therapeutics position peaked at $153K in Q4 2025.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.